Identification

Name
Bimatoprost
Accession Number
DB00905
Description

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.13,14,15,20 Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.16 It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.17

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 415.5656
Monoisotopic: 415.272258677
Chemical Formula
C25H37NO4
Synonyms
  • (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
  • Bimatoprost
  • Bimatoprostum
External IDs
  • AGN 192024
  • AGN-192024

Pharmacology

Indication

Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.13

Bimatoprost is also indicated to treat eyelash hypotrichosis.16

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment.13 Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes.13

Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness.13 Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.13

Mechanism of action

Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α.14 Bimatoprost mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways.13 It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow.6 Bimatoprost does not affect aqueous humor production.5

TargetActionsOrganism
AProstaglandin F2-alpha receptor
agonist
Humans
AProstaglandin E2 receptor EP1 subtype
agonist
Humans
AProstaglandin E2 receptor EP3 subtype
agonist
Humans
Absorption

This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study.13 By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing.13

One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.15

Volume of distribution

The volume of distribution at steady state is 0.67 L/kg.13,15. It penetrates the human cornea and sclera.15

Protein binding

Bimatoprost is about 88%-90% bound to plasma proteins.13,14

Metabolism

Bimatoprost is hydrolyzed to its active form, bimatoprost acid, in the eye.18 Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites.13 In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur.14 Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.14

Hover over products below to view reaction partners

Route of elimination

One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.13

Half-life

The elimination half-life of bimatoprost is approximately 45 minutes.13,14

Clearance

The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.13,14

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

No information is available at this time regarding bimatoprost overdose in humans. Provide supportive symptomatic treatment if an overdose occurs.13

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololBimatoprost may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Alclofenac.
AliskirenBimatoprost may increase the hypotensive activities of Aliskiren.
AmbrisentanBimatoprost may increase the hypotensive activities of Ambrisentan.
AminophenazoneThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Aminophenazone.
AmlodipineAmlodipine may increase the hypotensive activities of Bimatoprost.
AntipyrineThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Antipyrine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DurystaImplant10 ug/1Allergan, Inc.2020-03-04Not applicableUS flag
LatisseSolution / drops0.3 mg/1mLOphthalmicPhysicians Total Care, Inc.2009-07-242013-06-30US flag
LatisseSolution / drops0.3 mg/1mLOphthalmicAllergan, Inc.2009-01-26Not applicableUS flag
LatisseSolution0.03 %TopicalAllergan2010-11-01Not applicableCanada flag
LumiganSolution / drops0.3 mg/1mLOphthalmicAllergan, Inc.2001-03-22Not applicableUS flag
LumiganSolution / drops0.1 mg/1mLOphthalmicAllergan, Inc.2010-09-10Not applicableUS flag
LumiganSolution / drops0.3 mg/1mLOphthalmicPhysicians Total Care, Inc.2001-03-22Not applicableUS flag
LumiganSolution0.03 %OphthalmicAllergan2002-05-24Not applicableCanada flag
LumiganSolution / drops0.1 mg/1mLOphthalmicPhysicians Total Care, Inc.2011-09-14Not applicableUS flag
Lumigan PFSolutionOphthalmicAllerganNot applicableNot applicableCanada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-bimatoprostSolutionOphthalmicApotex CorporationNot applicableNot applicableCanada flag
Apo-bimatoprostSolutionTopicalApotex CorporationNot applicableNot applicableCanada flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicGland Pharma Limited2019-02-12Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicApotex Corp.2018-10-08Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicFosun Pharma USA Inc.2020-08-10Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicSomerset Therapeutics, Llc2019-06-19Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicSandoz Inc2016-12-06Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicGland Pharma Limited2019-02-12Not applicableUS flag
BimatoprostSolution3 ug/1mLTopicalHi-Tech Pharmacal Co., Inc.2018-09-26Not applicableUS flag
BimatoprostSolution / drops0.3 mg/1mLOphthalmicAlembic Pharmaceuticals Inc.2020-01-21Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
S01EE03 — Bimatoprost
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
N-acyl amines / Cyclopentanols / Benzene and substituted derivatives / Secondary carboxylic acid amides / Cyclic alcohols and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Cyclic alcohol / Cyclopentanol / Fatty amide / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid amide (CHEBI:51230)

Chemical Identifiers

UNII
QXS94885MZ
CAS number
155206-00-1
InChI Key
AQOKCDNYWBIDND-FTOWTWDKSA-N
InChI
InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
SMILES
CCNC(=O)CCC\C=C/C[[email protected]]1[[email protected]@H](O)C[[email protected]@H](O)[[email protected]@H]1\C=C\[[email protected]@H](O)CCC1=CC=CC=C1

References

Synthesis Reference

Jiang Xing Chen, "Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost." U.S. Patent US20090287003, issued November 19, 2009.

US20090287003
General References
  1. Chen MJ, Cheng CY, Chen YC, Chou CK, Hsu WM: Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther. 2006 Jun;22(3):188-93. [PubMed:16808680]
  2. Kruse P, Rieck P, Sherif Z, Liekfeld A: [Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?]. Klin Monbl Augenheilkd. 2006 Jun;223(6):534-7. [PubMed:16804825]
  3. Steinhauser SL: Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry. 2006 Apr;77(4):177-9. [PubMed:16567279]
  4. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ: The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45. [PubMed:11434936]
  5. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  6. Brubaker RF: Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S347-51. [PubMed:11434937]
  7. Christiansen GA, Nau CB, McLaren JW, Johnson DH: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004 Sep;111(9):1658-62. [PubMed:15350319]
  8. Easthope SE, Perry CM: Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19(3):231-48. [PubMed:12027782]
  9. Patil AJ, Vajaranant TS, Edward DP: Bimatoprost - a review. Expert Opin Pharmacother. 2009 Nov;10(16):2759-68. doi: 10.1517/14656560903292649. [PubMed:19874254]
  10. Woodward DF, Liang Y, Krauss AH: Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008 Feb;153(3):410-9. doi: 10.1038/sj.bjp.0707434. Epub 2007 Aug 27. [PubMed:17721551]
  11. Law SK: Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010 Apr 26;4:349-58. doi: 10.2147/opth.s6480. [PubMed:20463804]
  12. Jha AK, Sarkar R, Udayan UK, Roy PK, Jha AK, Chaudhary RKP: Bimatoprost in Dermatology. Indian Dermatol Online J. 2018 May-Jun;9(3):224-228. doi: 10.4103/idoj.IDOJ_62_16. [PubMed:29854658]
  13. FDA Approved Drug Products: Lumigan (bimatoprost) ophthalmic solution [Link]
  14. Allergen monograph, Bimatoprost [Link]
  15. Bitamaprost MedSafe NZ [Link]
  16. Latisse FDA label [Link]
  17. FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets [Link]
  18. Bimataprost metabolism, MDPI [Link]
  19. CaymanChem: Bimatoprost MSDS [Link]
  20. FDA Approved Products: Durysta (bimatoprost) implant for intracameral administration [Link]
Human Metabolome Database
HMDB0015041
KEGG Drug
D02724
PubChem Compound
5311027
PubChem Substance
46505334
ChemSpider
4470565
BindingDB
220120
RxNav
283810
ChEBI
51230
ChEMBL
CHEMBL1200963
ZINC
ZINC000004474405
Therapeutic Targets Database
DAP001217
PharmGKB
PA164748867
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
15M
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Bimatoprost
AHFS Codes
  • 52:40.28 — Prostaglandin Analogs
PDB Entries
2f38

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableGlaucoma4
4CompletedDiagnosticGlaucoma / Ocular Hypertension1
4CompletedTreatmentAlopecia Areata (AA) / Eyelash Hypotrichosis1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentApplication Site Pigmentation Changes / Glaucoma1
4CompletedTreatmentCataracts1
4CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines / Nasolabial Folds1
4CompletedTreatmentEndocrine ophthalmopathy1
4CompletedTreatmentEyelash Hypotrichosis1
4CompletedTreatmentGlaucoma2

Pharmacoeconomics

Manufacturers
  • Allergan inc
Packagers
  • Allergan Inc.
  • Physicians Total Care Inc.
Dosage Forms
FormRouteStrength
SolutionTopical
Solution / dropsOphthalmic0.01 %
Solution / dropsOphthalmic0.03 %
Solution / dropsOphthalmic5 mg/ml
Solution / dropsOphthalmic300 Mikrogramm/ml
Solution / dropsOphthalmic0.3 mg
Solution / drops; suspension / dropsOphthalmic0.3 MG/ML
Solution / dropsOphthalmic100 Mikrogramm/ml
SolutionTopical3 ug/1mL
Implant10 ug/1
Solution / dropsOphthalmic300 MCG/ML
Solution / dropsOphthalmic6.8 mg
Solution / drops; suspension / dropsOphthalmic0.12 mg
Solution / drops; suspension / dropsOphthalmic0.3 mg
SolutionOphthalmic0.12 mg
SolutionTopical0.03 %
SolutionOphthalmic0.03 %
Solution / dropsOphthalmic
Solution / dropsOphthalmic0.1 mg/1mL
Solution / dropsOphthalmic0.1 MG/ML
Solution / dropsOphthalmic0.3 mg/1mL
Solution / dropsOphthalmic0.3 MG/ML
Solution / dropsOphthalmic10 mg/100mL
Solution / dropsOphthalmic30 mg/100mL
SolutionOphthalmic0.1 mg
Solution / drops; suspension / dropsOphthalmic
Solution / drops; suspension / dropsOphthalmic0.1 MG/ML
SolutionOphthalmic
SolutionOphthalmic; Topical0.12 mg
SolutionConjunctival; Ophthalmic0.1 mg
SolutionConjunctival; Ophthalmic0.3 mg
Prices
Unit descriptionCostUnit
Lumigan .03% 7.5ml Bottle279.56USD bottle
Lumigan .03% 5ml Bottle171.4USD bottle
Lumigan .03% 2.5ml Bottle91.16USD bottle
Lumigan 0.03% eye drops44.82USD ml
Latisse 0.03% eyelash solution36.0USD ml
Lumigan 0.03 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6403649No2002-06-112012-09-21US flag
CA2585691No2009-05-192026-03-14Canada flag
CA2144967No2003-11-112013-09-09Canada flag
US8299118No2012-10-302025-03-16US flag
US8309605No2012-11-132025-03-16US flag
US8338479No2012-12-252025-03-16US flag
US8586630No2013-11-192025-03-16US flag
US8524777No2013-09-032025-03-16US flag
US8772338No2014-07-082025-03-16US flag
US9155716No2015-10-132025-03-16US flag
US9241918No2016-01-262025-03-16US flag
US7851504No2010-12-142027-06-13US flag
US8933120No2015-01-132025-03-16US flag
US8933127No2015-01-132025-03-16US flag
US8278353No2012-10-022025-03-16US flag
US7033605No2006-04-252020-10-20US flag
US8906962No2014-12-092021-01-31US flag
US8038988No2011-10-182023-08-25US flag
US8101161No2012-01-242024-05-25US flag
US8263054No2012-09-112023-01-15US flag
US8632760No2014-01-212023-01-15US flag
US8758733No2014-06-242023-01-15US flag
US8926953No2015-01-062023-01-15US flag
US8541466No2013-09-242021-01-31US flag
US7388029No2008-06-172022-01-21US flag
US7351404No2008-04-012024-05-25US flag
US9216183No2015-12-222023-01-15US flag
US9226931No2016-01-052023-01-15US flag
US8986715No2015-03-242023-01-15US flag
US9579270No2017-02-282021-01-31US flag
US8206737No2012-06-262027-04-07US flag
US8673341No2014-03-182025-02-19US flag
US9980974No2018-05-292034-10-31US flag
US10398707No2019-09-032024-04-30US flag
US9149428No2015-10-062026-12-19US flag
US7799336No2010-09-212029-04-24US flag
US8629185No2014-01-142031-07-15US flag
US10441543No2019-10-152026-12-19US flag
US9492316No2016-11-152034-10-31US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)63-67https://mri.cts-mrp.eu/Human/Downloads/PT_H_1188_001_PAR.pdf
boiling point (°C)629.8 https://mri.cts-mrp.eu/Human/Downloads/PT_H_1188_001_PAR.pdf
water solubilitysoluble in waterhttps://mri.cts-mrp.eu/Human/Downloads/PT_H_1188_001_PAR.pdf
logP3.2http://www.hmdb.ca/metabolites/HMDB0015041
pKa14.3, - 0.23http://www.hmdb.ca/metabolites/HMDB0015041
Predicted Properties
PropertyValueSource
Water Solubility0.0187 mg/mLALOGPS
logP3.41ALOGPS
logP2.63ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.35ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area89.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity122.83 m3·mol-1ChemAxon
Polarizability48.24 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.825
Caco-2 permeable-0.5699
P-glycoprotein substrateSubstrate0.5541
P-glycoprotein inhibitor INon-inhibitor0.8671
P-glycoprotein inhibitor IINon-inhibitor0.8616
Renal organic cation transporterNon-inhibitor0.8078
CYP450 2C9 substrateNon-substrate0.7703
CYP450 2D6 substrateNon-substrate0.7406
CYP450 3A4 substrateSubstrate0.552
CYP450 1A2 substrateNon-inhibitor0.6764
CYP450 2C9 inhibitorNon-inhibitor0.7695
CYP450 2D6 inhibitorNon-inhibitor0.6384
CYP450 2C19 inhibitorNon-inhibitor0.7632
CYP450 3A4 inhibitorNon-inhibitor0.757
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.7646
CarcinogenicityNon-carcinogens0.9257
BiodegradationNot ready biodegradable0.6415
Rat acute toxicity2.1085 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9251
hERG inhibition (predictor II)Non-inhibitor0.7822
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin f receptor activity
Specific Function
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis...
Gene Name
PTGFR
Uniprot ID
P43088
Uniprot Name
Prostaglandin F2-alpha receptor
Molecular Weight
40054.1 Da
References
  1. Sharif NA, Williams GW, Kelly CR: Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001 Dec 7;432(2-3):211-3. [PubMed:11740958]
  2. Sharif NA, Kelly CR, Crider JY: Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002 Aug;18(4):313-24. [PubMed:12222762]
  3. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708]
  4. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  5. Mintz EE: Group supervision: an experiential approach. Int J Group Psychother. 1978 Oct;28(4):467-9. [PubMed:689791]
  6. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832]
  7. Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD: Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15. [PubMed:17724194]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an importa...
Gene Name
PTGER1
Uniprot ID
P34995
Uniprot Name
Prostaglandin E2 receptor EP1 subtype
Molecular Weight
41800.655 Da
References
  1. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708]
  2. Ota T, Aihara M, Saeki T, Narumiya S, Araie M: The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3395-9. [PubMed:16877408]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding
Specific Function
Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition ...
Gene Name
PTGER3
Uniprot ID
P43115
Uniprot Name
Prostaglandin E2 receptor EP3 subtype
Molecular Weight
43309.335 Da
References
  1. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. [PubMed:14733708]
  2. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL: Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. doi: 10.1089/jop.2008.0089. [PubMed:19232013]
  3. Ota T, Aihara M, Saeki T, Narumiya S, Araie M: The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3395-9. [PubMed:16877408]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Allergen monograph, Bimatoprost [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Allergen monograph, Bimatoprost [Link]

Drug created on June 13, 2005 07:24 / Updated on November 29, 2020 03:54

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates